Audentes Therapeutics (NASDAQ:BOLD) was downgraded by stock analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating in a note issued to investors on Tuesday, The Fly reports.
Other research analysts also recently issued research reports about the company. ValuEngine downgraded Audentes Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Piper Jaffray Companies lowered shares of Audentes Therapeutics from an “overweight” rating to a “neutral” rating in a report on Tuesday. Mizuho reiterated a “buy” rating and set a $45.00 target price on shares of Audentes Therapeutics in a research report on Wednesday, August 7th. Evercore ISI raised shares of Audentes Therapeutics from an “in-line” rating to an “outperform” rating in a report on Wednesday, November 27th. Finally, Chardan Capital reissued a “buy” rating and set a $50.00 target price on shares of Audentes Therapeutics in a report on Sunday, October 6th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. Audentes Therapeutics has a consensus rating of “Hold” and a consensus price target of $42.00.
Shares of BOLD opened at $28.61 on Tuesday. Audentes Therapeutics has a 12-month low of $17.95 and a 12-month high of $41.65. The business has a 50-day simple moving average of $27.71 and a two-hundred day simple moving average of $33.11. The stock has a market cap of $1.33 billion, a PE ratio of -8.41 and a beta of 1.77.
Audentes Therapeutics (NASDAQ:BOLD) last posted its earnings results on Thursday, November 7th. The biotechnology company reported ($1.00) EPS for the quarter, beating the consensus estimate of ($1.07) by $0.07. During the same period in the prior year, the company earned ($0.97) earnings per share. As a group, equities analysts forecast that Audentes Therapeutics will post -4.13 earnings per share for the current fiscal year.
In related news, Director Louis G. Lange sold 10,000 shares of Audentes Therapeutics stock in a transaction that occurred on Monday, September 23rd. The stock was sold at an average price of $32.16, for a total transaction of $321,600.00. Following the transaction, the director now owns 276,044 shares of the company’s stock, valued at $8,877,575.04. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Matthew R. Patterson sold 14,426 shares of Audentes Therapeutics stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $30.00, for a total value of $432,780.00. Following the transaction, the chief executive officer now directly owns 127,820 shares in the company, valued at approximately $3,834,600. The disclosure for this sale can be found here. Insiders own 5.30% of the company’s stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Great Point Partners LLC lifted its stake in Audentes Therapeutics by 29.2% during the 3rd quarter. Great Point Partners LLC now owns 2,485,000 shares of the biotechnology company’s stock valued at $69,804,000 after acquiring an additional 562,063 shares in the last quarter. BlackRock Inc. grew its stake in shares of Audentes Therapeutics by 14.2% in the 2nd quarter. BlackRock Inc. now owns 3,333,445 shares of the biotechnology company’s stock worth $126,204,000 after acquiring an additional 413,768 shares in the last quarter. D. E. Shaw & Co. Inc. grew its stake in shares of Audentes Therapeutics by 118.6% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 592,947 shares of the biotechnology company’s stock worth $22,449,000 after acquiring an additional 321,756 shares in the last quarter. Millennium Management LLC raised its holdings in shares of Audentes Therapeutics by 49.2% in the third quarter. Millennium Management LLC now owns 773,279 shares of the biotechnology company’s stock valued at $21,721,000 after purchasing an additional 255,086 shares during the last quarter. Finally, Nuveen Asset Management LLC purchased a new stake in shares of Audentes Therapeutics in the second quarter valued at about $8,653,000. 98.08% of the stock is owned by institutional investors and hedge funds.
About Audentes Therapeutics
Audentes Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases caused by single gene defects. The company is developing AT132, which is in Phase I/II clinical studies for the treatment of X-linked myotubular myopathy (XLMTM); AT342 that is in Phase I/II clinical studies to treat crigler-najjar syndrome; AT845, which is in preclinical studies for the treatment of pompe disease; and AT307 to treat CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia.
Featured Story: Golden Cross
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.